1-(5-methoxy-2-methyl-phenyl)-piperazine | 180698-23-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(5-methoxy-2-methyl-phenyl)-piperazine
• 英文别名: 1-(5-Methoxy-2-methylphenyl)piperazine
• CAS: 180698-23-1
• 化学式: C₁₂H₁₈N₂O
• 分子量: 206.288
• InChiKey: WQWFTQWTQCGSDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate 、 1-(5-methoxy-2-methyl-phenyl)-piperazine 生成 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(5-methoxy-2-methylphenyl)piperazine
  参考文献：
  名称：

  Piperazine derivatives and methods for the preparation thereof and

  摘要：

  本发明涉及一般式(I)的新化合物及其酸加成盐。其中，R1和R2独立地表示氢、C1-C8烷基或选择性取代的C3-C6环状烷基，其中含有C3-C8；R3、R4、R5、R6和R7独立地表示氢、卤素、羟基、硝基、C1-C4较低酯基、C1-C4较低烷基、C1-C4较低烷氧基、芳基、芳基烷氧基或不饱和胺基；l为0-7的整数；m和n独立地为0-1的整数；W为碳或氮；X为氧、硫或选择性取代的亚胺基；Y为氮或氧；Z为氢、C1-C8烷氧基、芳氧基、C1-C4烷基胺、含有N1-N5的环胺基或羰基基团。上述式(I)的化合物不仅具有强烈的抗肿瘤活性，而且毒性较低，因此有望成为新型抗肿瘤剂。

  公开号：

  US05780472A1
• 作为产物：
  描述：

  3-[2-(5-Methoxy-2-methyl-phenylamino)-ethyl]-oxazolidin-2-one 在 氢溴酸 、 三乙胺 、 盐酸 作用下， 以 溶剂黄146 、 苯甲醚 、 乙醇 、 乙醚 、 乙酸乙酯 为溶剂， 反应 9.0h， 生成 1-(5-methoxy-2-methyl-phenyl)-piperazine
  参考文献：
  名称：

  [EN] 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS
  [FR] DERIVES DE PIPERAZINES 1-ARYL-4-SUSBTITUES UTILISES EN TANT QU'ANTAGONISTES DU CCR1 DANS LE TRAITEMENT DE L'INFLAMMATION ET DES TROUBLES IMMUNITAIRES

  摘要：

  提供了作为CCR1受体强效拮抗剂的化合物，并且已经在动物炎症测试中进一步确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用于鉴定竞争性CCR1拮抗剂的检测中具有用途。

  公开号：

  WO2003105853A1

文献信息

• Substituted piperazines
  申请人：ChemoCentryx, Inc.

  公开号：US20040162282A1

  公开（公告）日：2004-08-19

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并且这些化合物在动物炎症测试中进一步得到确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用作竞争性CCR1拮抗剂鉴定的检测中是有用的。
• [EN] 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS<br/>[FR] DÉRIVÉS DE 5-[3-[PIPÉRAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE À UTILISER EN TANT QU'INHIBITEURS D'ADAMTS 4 ET 5 POUR TRAITER PAR EXEMPLE L'ARTHROSE
  申请人：GALAPAGOS NV

  公开号：WO2017211666A1

  公开（公告）日：2017-12-14

  The present invention discloses 5-[3-[piperazin-l-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives according to Formula (I), wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS 4 and 5 for the prophylaxis or treatment of inflammatory diseases or diseases involving degradation of cartilage or disruption of cartilage homeostasis, such as e.g. osteoarthritis.

  本发明公开了根据式(I)的5-[3-[哌嗪-1-基]-3-氧代-丙基]-咪唑啉-2,4-二酮衍生物，其中R1、R2、R3a、R3b、R6a、R6b、下标n和Cy如本文所定义。本发明涉及抑制ADAMTS 4和5的化合物，用于预防或治疗炎症性疾病或涉及软骨降解或破坏软骨稳态的疾病，例如骨关节炎。
• Piperazine derivatives and process for the preparation thereof
  申请人：Samjin Pharmaceutical Co., Ltd.

  公开号：US06028195A1

  公开（公告）日：2000-02-22

  The present invention relates to novel compound having strong antimumor activities of the general formula(I) ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen, substituted or unsubstituted C.sub.1 -C.sub.8 alkyl, substituted or unsubstituted C.sub.3 -C.sub.6 cycloalkyl, substituted or unsubstituted C.sub.2 -C.sub.8 unsaturated alkyl, ketone, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.1 -C.sub.4 alkoxy, substituted or unsubstituted arylhydroxy, substituted or unsubstituted amino, C.sub.1 -C.sub.4 lower ester, C.sub.1 -C.sub.4 lower thioester, thiol, substituted or unsubstituted carboxyl, epoxy, substituted or unsubstituted C.sub.1 -C.sub.4 lower thioalkoxy; or R.sub.1 and R.sub.2 are fused to form C.sub.3 -C.sub.4 saturated or unsaturated chain; R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are independently hydrogen, halogen, hydroxy, nitro, C.sub.1 -C.sub.4 lower ester, C.sub.1 -C.sub.4 lower alkyl, C.sub.1 -C.sub.4 lower thioalkyl, substituted or unsubstituted C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.4 lower alkoxy, C.sub.1 -C.sub.4 lower thioalkoxy, substituted or unsubstituted aryl, substituted or unsubstituted lower arylalkoxy, substituted or unsubstituted lower alkylamino, or lower alkyl substituted or unsubstituted carbamate; or among R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7, two adjacent groups are bonded with each other to form 1,2-phenylene or 2,3-naphthylene; X is oxygen, sulfur, or substituted or unsubstituted imino; Y is bonded at the 3-position or 4-position of the aromatic ring part wherein Y is oxygen or --NR.sub.8 -- (wherein, R.sub.8 is the same with the above-mentioned R.sub.3.); Z is hydroxy, C.sub.1 -C.sub.4 lower alkoxy, C.sub.1 -C.sub.4 lower thioalkoxy, substituted or unsubstituted aryloxy, C.sub.1 -C.sub.4 lower alkylamino, substituted or unsubstituted cycloamino containing 1-5 nitrogen atoms; A is nitrogen or --CH.dbd.; its pharmaceutically acceptable acid addition salts and process for the preparation thereof.

  本发明涉及一种具有强抗肿瘤活性的新化合物，其通式为(I)： 其中R.sub.1和R.sub.2分别独立地为氢、取代或未取代的C.sub.1-C.sub.8烷基、取代或未取代的C.sub.3-C.sub.6环烷基、取代或未取代的C.sub.2-C.sub.8不饱和烷基、酮、取代或未取代的芳基、取代或未取代的C.sub.1-C.sub.4烷氧基、取代或未取代的芳基羟基、取代或未取代的氨基、C.sub.1-C.sub.4较低酯基、C.sub.1-C.sub.4较低硫酯基、硫醇、取代或未取代的羧基、环氧基、取代或未取代的C.sub.1-C.sub.4较低硫代烷氧基；或者R.sub.1和R.sub.2融合形成C.sub.3-C.sub.4饱和或不饱和链；R.sub.3、R.sub.4、R.sub.5、R.sub.6和R.sub.7独立地为氢、卤素、羟基、硝基、C.sub.1-C.sub.4较低酯基、C.sub.1-C.sub.4较低烷基、C.sub.1-C.sub.4较低硫代烷基、取代或未取代的C.sub.3-C.sub.6环烷基、C.sub.1-C.sub.4较低烷氧基、C.sub.1-C.sub.4较低硫代烷氧基、取代或未取代的芳基、取代或未取代的较低芳基氧基、取代或未取代的较低烷基氨基，或较低烷基取代或未取代的碳酸酯基；或在R.sub.3、R.sub.4、R.sub.5、R.sub.6和R.sub.7中，两个相邻的基团彼此连接形成1,2-苯基或2,3-萘基；X为氧、硫或取代或未取代的亚胺基；Y连接在芳香环部分的3-位或4-位，其中Y为氧或--NR.sub.8--（其中，R.sub.8与上述的R.sub.3相同）；Z为羟基、C.sub.1-C.sub.4较低烷氧基、C.sub.1-C.sub.4较低硫代烷氧基、取代或未取代的芳氧基、C.sub.1-C.sub.4较低烷基氨基、含有1-5个氮原子的取代或未取代的环氨基；A为氮或--CH.dbd.；其药学上可接受的酸盐和其制备方法。
• SUBSTITUTED PIPERAZINES
  申请人：Pennell Andrew M.K.

  公开号：US20080261987A1

  公开（公告）日：2008-10-23

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了一种作为CCR1受体强效拮抗剂的化合物，已经在动物炎症测试中进一步确认，这是CCR1标志性疾病状态之一。这些化合物通常是芳基哌嗪衍生物，可用于制药组合物、治疗CCR1介导疾病的方法，以及用作竞争性CCR1拮抗剂鉴定的控制物。
• VESAMICOL PIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME
  申请人：DAIICHI RADIOISOTOPE LABORATORIES, LTD.

  公开号：EP1205473A1

  公开（公告）日：2002-05-15

  A vesamicol piperazine derivative or a salt thereof of the following formula (I) is disclosed. wherein R is a hydrogen atom, amino group, nitro group, non-radioactive or radioactive iodine atom, trialkyl tin group, or trialkyl silyl group, and A is a substituted or unsubstituted aryl group or a heterocyclic group. The compound exhibits bonding properties precisely reflecting cholinergic neurons and high affinity to vesamicol receptors, and can specifically diagnose brain diseases, especially, Alzheimer's disease.

  本发明公开了一种下式（I）的维沙米醇哌嗪衍生物或其盐。 其中 R 是氢原子、氨基、硝基、非放射性或放射性碘原子、三烷基锡基或三烷基硅基，A 是取代或未取代的芳基或杂环基。 该化合物具有精确反映胆碱能神经元的键合特性以及与维沙米醇受体的高亲和性，可特异性诊断脑部疾病，尤其是阿尔茨海默氏症。